Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mutlu Hizal

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The New England Journal of Medicine|August 24, 2017
Adjuvant Capecitabine for Breast CancerMutlu Hizal, Mehmet A N Şendur, Bülent Yalçin
The New England Journal of Medicine|August 14, 2020
Atezolizumab and Bevacizumab in Hepatocellular CarcinomaMutlu Hizal, Mehmet A N Sendur, Bulent Yalcin
Expert Opinion on Biological Therapy|September 14, 2019
An update on immunotherapy options for urothelial cancerBurak Bilgin, Mehmet A N Sendur, Mutlu Hizal, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|February 6, 2019
Mutational status of lung cancer patients and survival outcomes for patients with limited brain metastasesMutlu Hizal, Mehmet Ali Nahit Sendur, Burak Bilgin, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|October 25, 2019
Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?Mutlu Hizal, Mehmet Ali Sendur, Burak Bilgin, et al.
Current Medical Research and Opinion|January 17, 2020
A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpointMutlu Hizal, Mehmet A N Sendur, Burak Bilgin, et al.
Scientific Reports|September 12, 2024
Interleukin-21 and Interleukin-23 levels in familial Mediterranean Fever before and after treatment: the role of cytokines in disease pathogenesisMutlu Hizal, Abdurrahman Tufan, Ridvan Mercan, et al.
Clinical Rheumatology|January 20, 2015
Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?Mutlu Hizal, Cosimo Bruni, Eloisa Romano, et al.
Journal of Cancer Research and Therapeutics|March 19, 2019
Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localizationBurak Bilgin, Mehmet Ali Nahit Sendur, Mutlu Hizal, et al.
Journal of Cancer Research and Clinical Oncology|February 2, 2021
The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangementBurak Bilgin, Mehmet Ali Nahit Şendur, Şebnem Yücel, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|August 24, 2017
Adjuvant Capecitabine for Breast CancerMutlu Hizal, Mehmet A N Şendur, Bülent Yalçin
The New England Journal of Medicine|August 14, 2020
Atezolizumab and Bevacizumab in Hepatocellular CarcinomaMutlu Hizal, Mehmet A N Sendur, Bulent Yalcin
Expert Opinion on Biological Therapy|September 14, 2019
An update on immunotherapy options for urothelial cancerBurak Bilgin, Mehmet A N Sendur, Mutlu Hizal, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|February 6, 2019
Mutational status of lung cancer patients and survival outcomes for patients with limited brain metastasesMutlu Hizal, Mehmet Ali Nahit Sendur, Burak Bilgin, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|October 25, 2019
Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?Mutlu Hizal, Mehmet Ali Sendur, Burak Bilgin, et al.
Current Medical Research and Opinion|January 17, 2020
A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpointMutlu Hizal, Mehmet A N Sendur, Burak Bilgin, et al.
Scientific Reports|September 12, 2024
Interleukin-21 and Interleukin-23 levels in familial Mediterranean Fever before and after treatment: the role of cytokines in disease pathogenesisMutlu Hizal, Abdurrahman Tufan, Ridvan Mercan, et al.
Clinical Rheumatology|January 20, 2015
Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?Mutlu Hizal, Cosimo Bruni, Eloisa Romano, et al.
Journal of Cancer Research and Therapeutics|March 19, 2019
Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localizationBurak Bilgin, Mehmet Ali Nahit Sendur, Mutlu Hizal, et al.
Journal of Cancer Research and Clinical Oncology|February 2, 2021
The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangementBurak Bilgin, Mehmet Ali Nahit Şendur, Şebnem Yücel, et al.
Pageof 3